Endocrine therapy of prostate cancer

Publisher Website
Google Scholar
Abstract
Cancer of the prostate is the most common neoplasm of adult men. In 1995, it was estimated that 244,000 men were diagnosed with prostate cancer and that 40,000 men died of this disease [ 1 ]. Although prostate-specific antigen (PSA) has greatly enhanced the early detection of prostate cancer, more than 50% of newly diagnosed prostate cancer patients already have advanced disease [ 2 - 6 ]. Up to 80% of these men will respond to hormonal ablation, yet the median survival of these patients is less than two years. Approximately 10% will live 10 years or longer [ 7 , 8 ].